- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
More ▼
Key statistics
On Friday, Silo Pharma Inc (SILO:NAQ) closed at 1.68, 38.14% above the 52 week low of 1.22 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.71 |
---|---|
High | 1.76 |
Low | 1.67 |
Bid | 1.65 |
Offer | 1.90 |
Previous close | 1.76 |
Average volume | 17.51k |
---|---|
Shares outstanding | 2.84m |
Free float | 2.66m |
P/E (TTM) | -- |
Market cap | 5.00m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of May 10 2024 20:59 BST.
More ▼